- Home
- PHT vs AVR Comparison
PHT vs AVR Comparison
Compare PHT & AVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHT
- AVR
- Stock Information
- Founded
- PHT 2002
- AVR 1999
- Country
- PHT United States
- AVR Australia
- Employees
- PHT N/A
- AVR N/A
- Industry
- PHT Investment Managers
- AVR
- Sector
- PHT Finance
- AVR
- Exchange
- PHT Nasdaq
- AVR NYSE
- Market Cap
- PHT 232.7M
- AVR 215.6M
- IPO Year
- PHT N/A
- AVR 2024
- Fundamental
- Price
- PHT $7.88
- AVR $8.25
- Analyst Decision
- PHT
- AVR Strong Buy
- Analyst Count
- PHT 0
- AVR 4
- Target Price
- PHT N/A
- AVR $16.50
- AVG Volume (30 Days)
- PHT 85.5K
- AVR 109.9K
- Earning Date
- PHT 01-01-0001
- AVR 01-01-0001
- Dividend Yield
- PHT 8.76%
- AVR N/A
- EPS Growth
- PHT N/A
- AVR N/A
- EPS
- PHT 0.98
- AVR N/A
- Revenue
- PHT N/A
- AVR $2,826,588.00
- Revenue This Year
- PHT N/A
- AVR N/A
- Revenue Next Year
- PHT N/A
- AVR $25.66
- P/E Ratio
- PHT $7.71
- AVR N/A
- Revenue Growth
- PHT N/A
- AVR N/A
- 52 Week Low
- PHT $6.41
- AVR $5.10
- 52 Week High
- PHT $7.60
- AVR $8.79
- Technical
- Relative Strength Index (RSI)
- PHT 48.90
- AVR N/A
- Support Level
- PHT $7.85
- AVR N/A
- Resistance Level
- PHT $7.96
- AVR N/A
- Average True Range (ATR)
- PHT 0.07
- AVR 0.00
- MACD
- PHT -0.01
- AVR 0.00
- Stochastic Oscillator
- PHT 21.43
- AVR 0.00
About PHT Pioneer High Income Fund Inc.
Pioneer High Income Trust is a closed-end management investment company. Its investment objective is to provide a high level of current income and to seek capital appreciation by investing predominantly in below investment grade (high-yield) debt securities, loans, and preferred stocks.
About AVR ANTERIS TECHNOLOGIES GLOBAL CORP
Anteris Technologies Global Corp. is a structural heart company committed to discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. Its product, the DurAVR THV system, represents a product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Its DurAVR THV system consists of a single-piece, biomimetic valve made with its proprietary ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold.